PET/CT in primary musculoskeletal tumours: a step forward

Area of Science:

• Oncology
• Radiology
• Nuclear Medicine

Background:

• Hybrid imaging, particularly positron emission tomography/computed tomography (PET/CT), is crucial for staging and managing various solid tumors.
• The application of PET/CT in evaluating musculoskeletal malignancy is not yet a routine clinical practice.
• While magnetic resonance imaging (MR) and computed tomography (CT) are established for cross-sectional imaging, evidence supports the selective use of PET/CT in musculoskeletal oncology.

Purpose of the Study:

• To review the current evidence regarding the clinical applications of PET/CT in primary musculoskeletal tumors.
• To discuss the potential future developments in PET/CT imaging for musculoskeletal malignancies.
• To explore the integration of novel PET tracers and hybrid PET/MR imaging in this field.

Main Methods:

• Literature review of current evidence on PET/CT in musculoskeletal tumors.
• Analysis of clinical applications and established roles of cross-sectional imaging (MR, CT).
• Discussion of emerging trends, including novel PET tracers and integrated PET/MR.

Main Results:

• PET/CT is increasingly recognized for its selective utility in managing patients with musculoskeletal malignancy.
• Established cross-sectional imaging modalities (MR, CT) have well-defined roles.
• Growing evidence suggests benefits of PET/CT beyond current routine use.

Conclusions:

• PET/CT offers valuable insights into primary musculoskeletal tumors, complementing existing imaging techniques.
• Further research and integration of advanced PET technologies are expected to enhance its role.
• Hybrid imaging modalities hold significant potential for improving patient management in musculoskeletal oncology.